Target intelligence / Profile preview

p53-induced noncoding RNA (PINCR)

Target
PINCR
Molecular classification
Other, Long noncoding RNA (lncRNA)
01

Overview

p53-induced noncoding RNA (PINCR) is a long noncoding RNA (lncRNA) encoded by the human genome (gene alias RP3-326I13.1), identified as a direct transcriptional target of the tumor suppressor p53. PINCR is induced over 100-fold in response to DNA damage in a p53-dependent manner, particularly in colorectal cancer cells. It promotes prosurvival functions by recruiting the RNA-binding protein Matrin 3 to enhancer regions of specific p53 target genes involved in G1 cell cycle arrest and resistance to apoptosis—precisely, BTG2, RRM2B, and GPX1. PINCR thus helps regulate a selective subset of the p53 transcriptional network, acting as a context-dependent pro-survival factor during genotoxic stress. Targeted deletion of PINCR impairs G1 cell cycle arrest and increases sensitivity to chemotherapy-induced cell death, but its direct targeting by pharmacological agents remains unreported. PINCR’s function highlights the crucial regulatory roles played by lncRNAs in tumor cell fate decisions following DNA damage[1][2].

Other names
PINCRRP3-326I13.1
02

Mechanism of action

Not directly targeted by drugs; PINCR regulates gene expression by binding to Matrin 3, which associates with p53 and enhancer regions of specific p53 target genes[1][2].

03

Biological functions

Cell cycle arrest regulationCell survival and prosurvival functionRegulation of a subset of p53 target genes (e.g., BTG2, RRM2B, GPX1) involved in G1 arrest and apoptosis
04

Disease associations

Cancer (specifically colorectal cancer)Tumorigenesis and tumor progression
05

Safety considerations

No specific safety concerns or therapeutic challenges reported for PINCR itself, as it is not currently a direct therapeutic target
06

Interacting drugs

None directly known; PINCR expression is induced by DNA-damaging agents such as doxorubicin and Nutlin-3, but no drugs are known to directly target PINCR itself
07

Biomarkers

Loss or knockout of PINCR results in impaired G1 arrest and increased sensitivity to chemotherapeutic drugs in colorectal cancer cells, suggesting potential use as a biomarker for cell survival response to DNA damage in p53-proficient tumors

Beyond the preview

Go deeper on p53-induced noncoding RNA (PINCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on p53-induced noncoding RNA (PINCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call